1Smith RE, Bryant J, DeCillis A, et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience [ J ]. J Clin Oncol,2003,21 ( 7 ) : 1195-1204.
2Diamandidou E, Buzdar AU, Smith TL,et al. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy:the University of Texas M. D. Anderson Cancer Center experience[J]. J Clin Oncol, 1996,14(10) :2722-2730.
3Sledge GW, editor. Adjuvant therapy for breast cancer cases [ J ].NIH Consens Statement ,2000,17( 1 ) :1-35.
4Kaplan HG, Malmgren JA, Atwood M. Leukemia incidence following primary breast carcinoma treatment[J]. Cancer,2004,101(7) : 1529-1536.
6Auxenfants E, Morel P, Lai JL, et al. Secondary acute lymphoblastic leukemia with t (4;11 ) :report on two cases and review of the literature[ J]. Ann Hematol, 1992,65 ( 3 ) : 143-146.
7Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms [ J ].Blood, 2002,100 ( 7 ) : 2292 -2302.
8Kobayashi Y, Hayashi Y, Ozawa K, et al. HRX gene rearrangement in secondary acute lymphoblastic leukemia [ J ]. Leuk Lymphoma, 1995,17 (5-6) :391-399.
9Secker-Walker LM, Moorman AV, Bain BJ, et al. Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnor-malities. EU Concerted Action 11 q23 Workshop [ J ]. Leukemia,1998,12(5):840-844.
10Andersen MK, Christiansen DH, Jensen BA,et al. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase Ⅱ inhibitors, an increasing problem:report on two new cases and review of the literature since 1992[J]. Br J Haematol,2001,114( 3 ) :539-543.
2Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues [ M ]. 4th ed. Lyon : IARC Press, 2008.
3Huh HJ, Lee SH, Yoo KH, et al. Therapy-related myeloid neoplasms in 39 Korean patients: a single institution experience[J]. Ann lab Med, 2013,33 (2) :97-104.
4Sonawane S, Gadgil N, Margam S. Therapy related myelodysplastic syndrome: a case report and review of literature [ J ]. Indian J Pathol Micrebiol,2011,54(2) :371-373.
5Kaplan H, Malmgren J, De Roos AJ. Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer : a population-based study [ J ]. Breast Cancer Res Treat, 2013,137 ( 3 ) : 863 -867.
6Chen Y, Estrov Z, Pierce S, et al. Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor [J]. Leuk Lymphoma,2015,56(4) : 1012-1019.
7Eghtedar A, Rodrignez I, Kantarjian H, et al. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide[J]. Leuk Lymphoma,2015,56(5) :1342-1345.
8Leone G, Pagano L, Ben-Yehuda D, et al. Therapy-related leukemia and myelodysplasia: susceptibility and incidence[J]. Haematologica, 2007,92(10) : 1389-1398.
9Leone G, Fianchi L, Pagano L, et al. Incidence and susceptibility to therapy-related myeloid neoplasms [ J ]. Chem Biol Interact, 2010, 184(1/2) :39-45.
10Praga C, Bergh J, Bliss J,et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in tfia|s of adjuvant eplrubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide [ J ]. J Clin Oncol, 2005,23(18) :4179.-4191.
